Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROMUS Element Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS Element Coronary Stent System in Unselected Patients in Routine Clinical Practice.

Next Previous
Trial Profile

PROMUS Element Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS Element Coronary Stent System in Unselected Patients in Routine Clinical Practice.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Thrombosis
  • Focus Therapeutic Use
  • Acronyms TE-Prove
  • Sponsors Boston Scientific Corporation

Most Recent Events

  • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
  • 24 Oct 2011 Additional locations (Belgium, England, France, Hungary, Ireland, Italy, Poland, Spain) added as reported by ClinicalTrials.gov.
  • 24 Oct 2011 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top